Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;3(8 Suppl):S17-23.
doi: 10.1097/WOX.0b013e3181ee0cfd.

May we strengthen the human natural defenses with bacterial lysates?

Affiliations

May we strengthen the human natural defenses with bacterial lysates?

Elisa Villa et al. World Allergy Organ J. 2010 Aug.

Abstract

During the last twenty years bacterial lysates have gained a new interest and their use has obtained a progressively larger consensus in the medical practice. They are commonly used as immunomodulators, in order to up-regulate immune responses against infectious damages. As a matter of fact, the role of these lysate seems relevant in upper and lower respiratory tract infections prevention, frequently observed both in paediatric and elder ages, and which represent a relevant problem also in terms of socio-economical implications. The effects of bacterial lysates as immunostimulatory agents have become the central point of many studies. The aim of those in vivo and in vitro studies was to understand and evaluate the capacity of this kind of treatments to create a better answer of the immune system against microbial infections, eventually leading to a reduction in their number. All the in vivo and in vitro findings analyzed support the evidence that bacterial lysates are powerful inducers of a specific immune response against bacterial infections. Both in paediatric and adult clinical trials, a positive trend has been found in terms of overall reduction of infection rates and duration, beneficial effect on symptoms, reduction in antibiotics use and possibility to improve the patient's quality of life in several diseases. Further well-designed trials in terms of blinding and randomization procedures and including a higher number of patients, selected according to the disease and its severity, are needed.

PubMed Disclaimer

References

    1. File TM. The epidemiology of respiratory tract infections. Semin Respir Infect. 2000;3:184–194. Review. - PubMed
    1. Rozy A. Chorostowska-Wynimko J. Bacterial immunostimulants-mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008;3:353–359. Review. - PubMed
    1. Collet JP. Shapiro P. Ernst P. Renzi T. Ducruet T. Robinson A. effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;3:1719–1724. - PubMed
    1. Steurer-Stey C. Bachmann LM. Steurer J. TramȲr MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest. 2004;3:1645–1655. - PubMed
    1. Schaad UB. Mɒtterlein R. Goffin H. BV-Child Study Group. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest. 2002;3:2042–2049. - PubMed